CliffBio
small molecule

DEFINITY RT

PERFLUTREN

Loss of exclusivityMay 2037latest FDA-listed patent expiry
CompanyLantheus Medical Imaging →View the full company profile on CliffBio

Drug detail

Brand nameDEFINITY RT
Active ingredientPERFLUTREN
Strength13.04MG/2ML (6.52MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2020
Marketing statusRX

Listed patents

PatentExpiresType
10588988May 2037use U-665
9789210March 2037use U-665
10583208March 2037use U-665
11857646March 2037use U-665
11266750March 2037use U-665
12161730March 2037use U-665
11925695March 2037use U-665
11529431March 2037use U-665
10583207December 2035use U-665
11395856December 2035substance, product
10022460December 2035substance, product

More from Lantheus Medical Imaging

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DEFINITY RT patent cliff — loss of exclusivity May 2037 | CliffBio